BioSpace News Archive

Dr. Haecker Meeks brings a deep expertise in emerging technologies and business strategy focused on the design and development of gene medicines and will lead business development for the company.

The Phase 1 study is designed to evaluate the safety, tolerability, and pharmacokinetic profile of CA-4948.

CanniMed Therapeutics Inc. reminds shareholders that the only way to see real value for their CanniMed shares is to vote the GREEN proxy FOR CanniMed’s acquisition of Newstrike Resources Ltd.

Carmot announced today that it has closed a $15M financing.

The goal of the collaboration was to deploy Circle’s rational design platform for macrocycle therapeutics in order to improve the drug-like characteristics of an existing macrocycle compound, and in particular to develop a cell permeable, orally bioavailable compound with enhanced target affinity.

These new patents add to the over 800 issued or pending patents worldwide and address many of BioTime’s key programs, including OpRegen.

This new aqueous system delivers a more streamlined application process, reducing coating time from days to hours and improving manufacturing safety through the elimination of organic solvents.

Osel, Inc. today announced the first patient has been dosed in a new clinical study launched in collaboration with five Danish fertility clinics and Statens Serum Institute to determine whether LACTIN-V can improve the success rate of in vitro fertilization (IVF) for infertile women with abnormal vaginal microbiota (AVM).

Kymriah became the first CAR-T cell therapy to receive regulatory approval when it was approved by the FDA in August 2017.

Regen BioPharma (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6.